Evidence map›Paper›PMID 34990589›Full record

ArticleDevelopmental cell2022

YAP1 and PRDM14 converge to promote cell survival and tumorigenesis.

Miju Kim, Seav Huong Ly, Yingtian Xie, Gina N Duronio, Dane Ford-Roshon, Justin H Hwang, Rita Sulahian, Jonathan P Rennhack, Jonathan So, Ole Gjoerup and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Developmental cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. PRDM Proteins Orchestrate Colorectal Cancer Tumorigenesis.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. CaCellular signalling · 2023
    Review
  11. Article
  12. New insights into the ambivalent role of YAP/TAZ in human cancers.Journal of experimental & clinical cancer research : CR · 2023
    Review
  13. Article
  14. Knowledge base and emerging trends in YAP1 research.American journal of translational research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Miju KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Seav Huong LyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Yingtian XieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Gina N DuronioDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Dane Ford-RoshonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Justin H HwangMasonic Cancer Center and Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Rita SulahianDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Jonathan P RennhackDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Jonathan SoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Ole GjoerupDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Jessica A TalamasDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Maximilien GrandclaudonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Henry W LongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
John G DoenchBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Nilay S SethiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Marios GiannakisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
William C HahnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: william_hahn@dfci.harvard.edu.
Broad Institute · USDana-Farber Cancer Institute · USUniversity of Minnesota · US

Funding

PROJECT 4: Interrogating PP2A Signaling in Human CancersP01CA203655 · NCI · DANA-FARBER CANCER INST · PI DECAPRIO, JAMES A. · 2017 to 2021
$8.0M
The Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8M
Systematic identification of oncogenic KRAS synthetic lethal interactionsU01CA199253 · NCI · BROAD INSTITUTE, INC. · PI HAHN, WILLIAM C. · 2015 to 2019
$3.7M
Integration of early genetic alterations and inflammation in gastroesophageal premalignancyK08DK120930 · NIDDK · DANA-FARBER CANCER INST · PI SETHI, NILAY · 2019 to 2023
$790k
The Role of E2F2 in HER2 Positive Breast CancerK00CA212221 · NCI · DANA-FARBER CANCER INST · PI RENNHACK, JONATHAN · 2018 to 2021
$366k
NCI NIH HHS K00 CA212221NCI NIH HHS P01 CA203655NCI NIH HHS U01 CA176058NCI NIH HHS U01 CA199253NIDDK NIH HHS K08 DK120930
6 · The paper itself

Abstract

The transcriptional co-activator YAP1 oncogene is the downstream effector of the Hippo pathway, which regulates tissue homeostasis, organ size, regeneration, and tumorigenesis. Multiple cancers are dependent on sustained expression of YAP1 for cell proliferation, survival, and tumorigenesis, but the molecular basis of this oncogene dependency is not well understood. To identify genes that can functionally substitute for YAP1, we performed a genome-scale genetic rescue screen in YAP1-dependent colon cancer cells expressing an inducible YAP1-specific shRNA. We found that the transcription factor PRDM14 rescued cell proliferation and tumorigenesis upon YAP1 suppression in YAP1-dependent cells, xenografts, and colon cancer organoids. YAP1 and PRDM14 individually activated the transcription of calmodulin 2 (CALM2) and a glucose transporter SLC2A1 upon YAP1 suppression, and CALM2 or SLC2A1 expression was required for the rescue of YAP1 suppression. Together, these findings implicate PRDM14-mediated transcriptional upregulation of CALM2 and SLC2A1 as key components of oncogenic YAP1 signaling and dependency.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCalmodulinCarcinogenesisCell Line, TumorCell ProliferationCell SurvivalColonic NeoplasmsDNA-Binding ProteinsGene ExpressionGene Expression Regulation, NeoplasticGlucose Transporter Type 1HumansMiceMice, NudeOrganoidsAdaptor Proteins, Signal TransducingCALM2 protein, humanCalmodulinDNA-Binding ProteinsGlucose Transporter Type 1PhosphoproteinsPRDM14 protein, humanRNA-Binding ProteinsSLC2A1 protein, humanTranscription FactorsYAP1 protein, humanYAP-Signaling Proteinscolon cancerHippo pathwayKRASoncogene addictionPRDM14resistanceYAP1

Identifiers

PMID34990589
PMCPMC8827663
OpenAlexW4206356040

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.